The costs of developing biosimilar drugs can be reduced

The higher the biosimilarity and risk-benefit demonstrated via quality assays and comprehensive comparability studies with a reference medicine, the shorter the clinical trial programs for a biosimilar are likely to be accepted by the regulators.